A pharmacokinetic standard for babies and adults

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 2941-2952

  Holford, Nick ^a   Heo, Young A ^a   Anderson, Brian ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adults; Allometric scaling; Clearance; Clinical pharmacokinetics; Glomerular filtration; Maturation; Pediatric; Premature babies; Renal clearance; Standard

Indexed keywords

ACICLOVIR; AMIKACIN; AMPHOTERICIN; BUSULFAN; CARVEDILOL; CIPROFLOXACIN; CLONIDINE; CYCLOSPORIN; DEXMEDETOMIDINE; DIAZEPAM; DICLOFENAC; FLUCONAZOLE; GENTAMICIN; INDOMETACIN; ITRACONAZOLE; KETAMINE; KETOROLAC; LAMIVUDINE; LEVOBUPIVACAINE; LOPINAVIR; MELATONIN; MIDAZOLAM; MORPHINE; ONDANSETRON; PANTOPRAZOLE; PARACETAMOL; PENCICLOVIR; PHENOBARBITAL; PROPOFOL; UNINDEXED DRUG;

ARTICLE; BABY; BODY COMPOSITION; DRUG BINDING SITE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; MATURATION; PHARMACOKINETICS; PREMATURITY; STANDARD;

ADULTS; ALLOMETRIC SCALING; CLEARANCE; CLINICAL PHARMACOKINETICS; GLOMERULAR FILTRATION; MATURATION; PEDIATRIC; PREMATURE BABIES; RENAL CLEARANCE; STANDARD;

ADULT; AGE FACTORS; CHILD, PRESCHOOL; HUMANS; INFANT; KIDNEY; METABOLIC CLEARANCE RATE; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL;

EID: 84881609015     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23574     Document Type: Review

References (102)

1. Sheiner L, Tozer T. 1978. Clinical pharmacokinetics: The use of plasma concentrations of drugs. In Clinical pharmacology: Basic principles of therapeutics; Melmon K, Morelli H, Eds. New York: Macmillan, pp. 71-109.
2. Holford NH. 1999. Target concentration intervention: Beyond Y2K. Br J Clin Pharmacol 48(1):9-13.
3. Moore P. 1998. Children are not small adults. Lancet 352(9128):630.
4. Bouzom F, Walther B. 2008. Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling. Fundam Clin Pharmacol 22(6):579-587.
5. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303-332.
6. Butler JM, Begg EJ. 2008. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 47(5):297-321.
7. Polasek TM, Patel F, Jensen BP, Sorich MJ, Wiese MD, Doogue MP. 2013. Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol 75(4):1019-1028.
8. Holford NH. 1996. A size standard for pharmacokinetics. Clin Pharmacokinet 30(5):329-332.
9. Gupta M, Brans Y. 1978. Gastric retention in neonates. Pediatrics 62:26-29.
10. Grand RJ, Watkins JB, Torti FM. 1976. Development of the human intestinal tract: A review. Gastroenterology 70:790-810.
11. Liang J, Co E, Zhang M, Pineda J, Chen JD. 1998. Development of gastric slow waves in preterm infants measured by electrogastrography. Am J Physiol 274(3 Pt 1):G503-G508.
12. Carlos MA, Babyn PS, Marcon MA, Moore AM. 1997. Changes in gastric emptying in early postnatal life. J Pediatr 130(6):931-937.
13. Rodbro P, Krasilnikoff PA, Christiansen PM. 1967. Parietal cell secretory function in early childhood. Scand J Gastroenterol 2(3):209-213.
14. Agunod M, Yamaguchi N, Lopez R, Luhby AL, Glass GB. 1969. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 14(6):400-414.
15. Huang NN, High RH. 1953. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J Pediatr 42(6):657-658.
16. Suchy FJ, Balistreri WF, Heubi JE, Searcy JE, Levin RS. 1981. Physiologic cholestasis: Elevation of the primary serum bile acid concentrations in normal infants. Gastroenterology 80(5 pt 1):1037-1041.
17. Poley JR, Dower JC, Owen Jr. CA, Stickler GB. 1964. Bile acids in infants and children. J Lab Clin Med 63:838-846.
18. Karl HW, Rosenberger JL, Larach MG, Ruffle JM. 1993. Transmucosal administration of midazolam for premedication of pediatric patients. Comparison of the nasal and sublingual routes. Anesthesiology 78(5):885-891.
19. Wheeler M, Birmingham PK, Dsida RM, Wang Z, Cote CJ, Avram MJ. 2002. Uptake pharmacokinetics of the Fentanyl Oralet in children scheduled for central venous access removal: Implications for the timing of initiating painful procedures. Pediatr Anesth 12(7):594-599.
20. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR. 1975. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55(2):347-359.
21. Friis-Hansen B. 1961. Body water compartments in children: Changes during growth and related changes in body composition. Pediatrics 28:169-181.
22. Kelman AW, Thomson AH, Whiting B, Bryson SM, Steedman DA, Mawer GE, Samba-Donga LA. 1984. Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol 18(5):685-692.
23. Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH. 2002. Acetaminophen developmental pharmacokinetics in premature neonates and infants: A pooled population analysis. Anesthesiology 96(6):1336-1345.
24. Holford NH, Ma SC, Anderson BJ. 2012. Prediction of morphine dose in humans. Paediatr Anaesth 22(3):209-222.
25. Tod M, Lokiec F, Bidault R, De Bony F, Petitjean O, Aujard Y. 2001. Pharmacokinetics of oral acyclovir in neonates and in infants: A population analysis. Antimicrob Agents Chemother 45(1):150-157.
26. Thummel KE, Shen DD, Isoherranen N. 2012. Appendix II design and optimization of dosage regimens: Pharmacokinetic data. In Goodman & Gilman's the pharmacological basis of therapeutics; Brunton LL, Chabner BA, Knollmann BC, Eds. 12 ed. McGraw Hill, pp. 1891-1990.
27. Allegaert K, Scheers I, Cossey V, Anderson BJ. 2008. Covariates of amikacin clearance in neonates: The impact of postnatal age on predictability. Drug Metab Lett 2(4):286-289.
28. Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. 2005. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 49(12):5092-5098.
29. Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D, Sahajwalla C, Mehta M, Gobburu JV. 2007. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol 47(1):101-111.
30. Holford NH, McCune J, Barrett JH. 2013. Busulfan pharmacokinetics in neonates, infants, children and adults PAGANZ Annual meeting February 14. Brisbane.
31. Albers S, Meibohm B, Mir TS, Laer S. 2008. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol 65(4):511-522.
32. Thuo N, Ungphakorn W, Karisa J, Muchohi S, Muturi A, Kokwaro G, Thomson AH, Maitland K. 2011. Dosing regimens of oral ciprofloxacin for children with severe malnutrition: A population pharmacokinetic study with Monte Carlo simulation. J Antimicrob Chemother 66(10):2336-2345.
33. Xie HG, Cao YJ, Gauda EB, Agthe AG, Hendrix CW, Lee H. 2011. Clonidine clearance matures rapidly during the early postnatal period: A population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. J Clin Pharmacol 51(4):502-511.
34. Potts AL, Larsson P, Eksborg S, Warman G, Lonnqvist PA, Anderson BJ. 2007. Clonidine disposition in children; a population analysis. Paediatr Anaesth 17(10):924-933.
35. Fanta S, Jonsson S, Backman JT, Karlsson MO, Hoppu K. 2007. Developmental pharmacokinetics of ciclosporin-A population pharmacokinetic study in paediatric renal transplant candidates. Br J Clin Pharmacol 64(6):772-784.
36. Potts AL, Anderson BJ, Warman GR, Lerman J, Diaz SM, Vilo S. 2009. Dexmedetomidine pharmacokinetics in pediatric intensive care-A pooled analysis. Paediatr Anaesth 19(11):1119-1129.
37. Anttila M, Penttila J, Helminen A, Vuorilehto L, Scheinin H. 2003. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol 56(6):691-693.
38. Standing JF, Tibboel D, Korpela R, Olkkola KT. 2011. Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1-12 years. Paediatr Anaesth 21(3):316-324.
39. Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin Jr. DK, Sullivan JE, Ramey N, Jayaraman B, Hoppu K, Adamson PC, Gastonguay MR, Barrett JS. 2008. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 52(11):4043-4049.
40. Lopez SA, Mulla H, Durward A, Tibby SM. 2010. Extended-interval gentamicin: Population pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med 11(2):267-274.
41. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH. 2009. Human renal function maturation: A quantitative description using weight and postmenstrual age. Pediatr Nephrol 24(1):67-76.
42. Smyth JM, Collier PS, Darwish M, Millership JS, Halliday HL, Petersen S, McElnay JC. 2004. Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. Br J Clin Pharmacol 58(3):249-258.
43. Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. 2006. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 45(11):1099-1114.
44. Brunette KE, Anderson BJ, Thomas J, Wiesner L, Herd DW, Schulein S. 2011. Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures. Paediatr Anaesth 21(6):653-662.
45. Clements JA, Nimmo WS. 1981. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 53(1):27-30.
46. Drover DR, Hammer GB, Anderson BJ. 2012. The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. Anesth Analg 114(6):1270-1276.
47. Bouazza N, Hirt D, Blanche S, Frange P, Rey E, Treluyer JM, Urien S. 2011. Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents. Antimicrob Agents Chemother 55(7):3498-3504.
48. Moore KH, Yuen GJ, Hussey EK, Pakes GE, Eron Jr. JJ, Bartlett JA. 1999. Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 43(12):3025-3029.
49. Toublanc N, Lovern M, Sargentini-Maier ML, Stockis A. 8th European Congress on Epileptology, Berlin; September 22-25, 2008, pp 142.
50. Chalkiadis GA, Anderson BJ. 2006. Age and size are the major covariates for prediction of levobupivacaine clearance in children. Paediatr Anaesth 16(3):275-282.
51. Gristwood RW, Greaves JL. 1999. Levobupivacaine: A new safer long acting local anaesthetic agent. Exp Opin Investig Drugs 8(6):861-876.
52. Urien S, Firtion G, Anderson ST, Hirt D, Solas C, Peytavin G, Faye A, Thuret I, Leprevost M, Giraud C, Lyall H, Khoo S, Blanche S, Treluyer JM. 2011. Lopinavir/ritonavir population pharmacokinetics in neonates and infants. Br J Clin Pharmacol 71(6):956-960.
53. Merchant NM, Azzopardi DV, Hawwa AF, McElnay JC, Middleton B, Arendt J, Arichi T, Gressens P, Edwards AD. 2013. Pharmacokinetics of melatonin in preterm infants. Br J Clin Pharmacol. DOI 10.1111/bcp.12092
54. Mallo C, Zaidan R, Galy G, Vermeulen E, Brun J, Chazot G, Claustrat B. 1990. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 38(3):297-301.
55. Anderson BJ, Larsson P. 2011. A maturation model for midazolam clearance. Paediatr Anaesth 21(3):302-308.
56. Mondick JT, Johnson BM, Haberer LJ, Sale ME, Adamson PC, Cote CJ, Croop JM, Russo MW, Barrett JS, Hoke JF. 2010. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. Eur J Clin Pharmacol 66(1):77-86.
57. Knebel W, Tammara B, Udata C, Comer G, Gastonguay MR, Meng X. 2011. Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. J Clin Pharmacol 51(3):333-345.
58. Anderson BJ, Holford NHG. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24 (1):25-36.
59. Mohammed BS, Engelhardt T, Cameron GA, Cameron L, Hawksworth GM, Hawwa AF, McElnay J, Helms PJ, McLay JS. 2012. Population pharmacokinetics of single-dose intravenous paracetamol in children. Br J Anaesth 108(5):823-829.
60. Blumer J, Rodriguez A, Sanchez PJ, Sallas W, Kaiser G, Hamed K. 2010. Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. Antimicrob Agents Chemother 54(5):2032-2041.
61. Ogungbenro K, Matthews I, Looby M, Kaiser G, Graham G, Aarons L. 2009. Population pharmacokinetics and optimal design of paediatric studies for famciclovir. Br J Clin Pharmacol 68(4):546-560.
62. Shellhaas RA, Ng CM, Dillon CH, Barks JD, Bhatt-Mehta V. 2013. Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Pediatr Crit Care Med 14(2):194-202.
63. Allegaert K, de Hoon J, Verbesselt R, Naulaers G, Murat I. 2007. Maturational pharmacokinetics of single intravenous bolus of propofol. Paediatr Anaesth 17(11):1028-1034.
64. Cortinez LI, Anderson BJ, Penna A, Olivares L, Munoz HR, Holford NH, Struys MM, Sepulveda P. 2010. Influence of obesity on propofol pharmacokinetics: Derivation of a pharmacokinetic model. Br J Anaesth 105(4):448-456.
65. Schuttler J, Ihmsen H. 2000. Population pharmacokinetics of propofol: A multicenter study. Anesthesiology 92(3):727-738.
66. Salman S, Griffin S, Kose K, Pitus N, Winmai J, Moore B, Siba P, Ilett KF, Mueller I, Davis TM. 2011. Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy. Antimicrob Agents Chemother 55(4):1693-1700.
67. Weidekamm E, Plozza-Nottebrock H, Forgo I, Dubach UC. 1982. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull World Health Organ 60(1):115-122.
68. Hendriksen IC, Maiga D, Lemnge MM, Mtove G, Gesase S, Reyburn H, Lindegardh N, Day NP, von Seidlein L, Dondorp AM, Tarning J, White NJ. 2013. Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria. Antimicrob Agents Chemother 57(2):775-783.
69. Hawwa AF, Westwood PM, Collier PS, Millership JS, Yakkundi S, Thurley G, Shields MD, Nunn AJ, Halliday HL, McElnay JC. 2013. Prophylactic ranitidine treatment in critically ill children-A population pharmacokinetic study. Br J Clin Pharmacol 75(5):1265-1276.
70. Rigby-Jones AE, Priston MJ, Sneyd JR, McCabe AP, Davis GI, Tooley MA, Thorne GC, Wolf AR. 2007. Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. Br J Anaesth 99(2):252-261.
71. Aarons L, Sadler B, Pitsiu M, Sjovall J, Henriksson J, Molnar V. 2011. Population pharmacokinetic analysis of ropivacaine and its metabolite 2', 6'-pipecoloxylidide from pooled data in neonates, infants, and children. Br J Anaesth 107(3):409-424.
72. Thomas JM, Schug SA. 1999. Recent advances in the pharmacokinetics of local anaesthetics. Long-acting amide enantiomers and continuous infusions. Clin Pharmacokinet 36(1):67-83.
73. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, Andre JL, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E. 2009. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 86(6):609-618.
74. Tsuda Y, Tatami S, Yamamura N, Tadayasu Y, Sarashina A, Liesenfeld KH, Staab A, Schafer HG, Ieiri I, Higuchi S. 2010. Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. Br J Clin Pharmacol 70(1):88-101.
75. Bouazza N, Urien S, Hirt D, Frange P, Rey E, Benaboud S, Foissac F, Blanche S, Treluyer JM. 2011. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. J Acquir Immune Defic Syndr 58(3):283-288.
76. Larsson P, Anderson BJ, Norman E, Westrin P, Fellman V. 2011. Thiopentone elimination in newborn infants: Exploring Michaelis-Menten kinetics. Acta Anaesthesiol Scand 55(4):444-451.
77. Hennig S, Norris R, Kirkpatrick CM. 2008. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis-A population pharmacokinetic study. Br J Clin Pharmacol 65(4):502-510.
78. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. 2002. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother 50(4):553-559.
79. Allegaert K, Anderson BJ, Verbesselt R, Debeer A, de Hoon J, Devlieger H, Van Den Anker JN, Tibboel D. 2005. Tramadol disposition in the very young: An attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth 95(2):231-239.
80. Hullett B, Salman S, O'Halloran SJ, Peirce D, Davies K, Ilett KF. 2012. Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children. Anesthesiology 116(5):1124-1133.
81. Karim A, Laurent A, Slater ME, Kuss ME, Qian J, Crosby-Sessoms SL, Hubbard RC. 2001. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 41(10):1111-1119.
82. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH. 2007. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 63(1):75-84.
83. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126.
84. Savage VM, Gillooly JF, Woodruff WH, West GB, Allen AP, Enquist BJ, Brown JH. 2004. The predominance of quarter-power scaling in biology. Funct Ecol 18(2):257-282.
85. Welzing L, Ebenfeld S, Dlugay V, Wiesen MH, Roth B, Mueller C. 2011. Remifentanil degradation in umbilical cord blood of preterm infants. Anesthesiology 114(3):570-577.
86. Engle WA. 2004. Age terminology during the perinatal period. Pediatrics 114(5):1362-1364.
87. Chen N, Aleksa K, Woodland C, Rieder M, Koren G. 2006. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 21(2):160-168.
88. Anderson BJ, Holford NHG. 2011. Tips and traps analyzing pediatric PK data. Pediatr Anesth 21(3):222-237.
89. Anderson BJ, Holford NHG. 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24(1):25-36.
90. Sumpter AL, Holford NHG. 2011. Predicting weight using postmenstrual age-Neonates to adults. Pediatr Anesth 21(3):309-315.
91. Anderson BJ, McKee AD, Holford NHG. 1997. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet 33(5):313-327.
92. Wang C, Peeters MY, Allegaert K, van Oud-Alblas HJ, Krekels EH, Tibboel D, Danhof M, Knibbe CA. 2012. A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res 29(6):1570-1581.
93. McLeay SC, Morrish GA, Kirkpatrick CMJ, Green B. 2012. The relationship between drug clearance and body size: Systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 51(5):319-330.
94. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. 2005. Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transpl 11(12):1481-1493.
95. Krekels EHJ, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, Knibbe CAJ. 2012. From pediatric covariate model to semiphysiological function for maturation: Part II[mdash]sensitivity to physiological and physicochemical properties. CPT: Pharmacomet Syst Pharmacol 1:e10.
96. Benet L, Oie S, Schwartz J. 1996. Appendix II design and optimization of dosage regimens: Pharmacokinetic data. In Goodman & Gilman's the pharmacological basis of therapeutics; Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A, Eds. 9 ed. McGraw Hill, New York, pp. 1707-1792.
97. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
98. Schwartz GJ. 1992. Does kL/PCr estimate GFR, or does GFR determine k? Pediatr Nephrol 6(6):512-515.
99. Mould DR, Holford NH, Schellens JH, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G. 2002. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71(5):334-348.
100. Matthews I, Kirkpatrick C, Holford N. 2004. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 58(1):8-19.
101. Fourtillan JB, Brisson AM, Gobin P, Ingrand I, Decourt JP, Girault J. 2000. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm Drug Dispos 21(1):15-22.
102. Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E. 2012. External evaluation of population pharmacokinetic models of vancomycin in neonates: The transferability of published models to different clinical settings. Br J Clin Pharmacol. [Epub ahead of print.]